Available Patient Support Program | Number of patients | Eligible Patients | Required Documents |
What will the patient go through? | How can we support you? | Frequently Asked Questions | Medical Inquiries |
Available Patient Support Programs
Enabling access to treatment
Groundbreaking advances in healthcare are only meaningful when they reach the people who need them, and this is why we are committed to supporting our patients through their disease journey by offering them patient support programs tailored to their needs.
Oncology programs |
Treatment supported by Roche Cares Program |
Patient’s Reimbursement Body | Financial Services |
---|---|---|---|
Perjeta® |
NSSF (in-hospital) |
|
|
Kadcyla® |
NSSF (in-hospital) |
|
|
Herceptin® SC |
NSSF (Retail Pharmacy) |
|
|
Alecensa® |
NSSF (Retail Pharmacy) |
|
|
Tecentriq® |
NSSF (in-hospital) |
|
|
Hematology |
Gazyva® |
NSSF (In-hospital) |
|
CNS |
Ocrevus® |
NSSF (In-hospital) COOP (In-hospital) |
|
RA programs |
Actemra® SC |
NSSF (Retail Pharmacy) |
|
Foundation |
FoundationOne®CDx FoundationOne®Heme FoundationOne®LiquidCDx |
All reimbursement bodies |
|
Number of Patients enrolled in Roche Programs since 2016
More Than Numbers.
Oncology and Hematology |
Central Nervous System |
Rheumatoid Arthritis |
Foundation Medicine Testing |
138 patients |
50 patients |
57 patients |
103 patients
|
Eligible patients
Understanding the Difference Can Make a Difference.
Eligibility*:
Patients covered by NSSF who are prescribed a Roche product by their treating physicians as per local label and NSSF approval.
* For Ocrevus - NSSF + COOP
* For FMI testing - All reimbursement bodies
Required documents
Understanding the Difference Can Make a Difference.
Doctor Documents needed
|
Patient Documents needed
* If applicable
|
For Ocrevus
For Tecentriq
For Perjeta,
Kadcyla, Alecensa
For FMI Testing
What will the patient go through?
The journey.
Step 1 |
Step 2 |
Step 3 |
Step 4 |
Step 5 |
Treating physician informs patient about the program details, hand him/her the signed consent form, and shares the number of the program support center.
|
Patient will contact the support center to understand the program requirements and needed documents. |
Support center will assess patient's eligibility for the program. If eligible the center will contact the patient and follow up on enrollment steps. |
After successful enrollment to the program, the support center will provide different types of support. |
Support center will keep following up with the enrolled patient(s) on his/her treatment until treatment discontinuation. |
How can we support you?
We are here to help
Roche representative
Support Center Representatives
For Ocrevus
Support Center Representatives
For Tecentriq,
Herceptin
and Actemra
Support Center Representatives
For Perjeta,
Kadcyla, Gazyva,
Alecensa, Hemlibra
Frequently asked questions
Questions & Answers
-
My patient is already on the treatment, can I still enroll him in the product program?
If the patient meets program’s eligibility criteria, whether newly or previously on the treatment, patient can always benefit from Co-payment Support.
As for the Payment Facilitation Support services, they are applicable at treatment initiation exclusively.
-
Why do I need to sign the informed consent form?
Physician’s signature is required since the informed consent form includes patient treatment plan; by signing the consent form the physician confirms patient’s medical eligibility. Besides medical eligibility, Rochecares ensures by consent signature physician approval on patient’s enrollment in the program.
-
Besides Medical Eligibility, how is eligibility determined?
This program has been designed to support patients covered by the National Social Security Fund (NSSF) in Lebanon and who need support affording the cost for their Roche prescribed treatment. Patients eligible for support are patients with a valid medical prescription from a treating physician and enrolled in the NSSF.
As for patients prescribed “Foundation Medicine” test, Roche Cares PSP will provide them with the logistical support needed.
-
What is my role in the program?
After you have independently diagnosed and prescribed your patient a treatment/ test plan which involves taking a Roche Lebanon SARL product/ service, you are kindly asked to:
- Inform the patient about the availability of RocheCares financial assistance/logistical support program
- Complete with the patient the informed consent form
- Submit the consent form to IQVIA and/or refer the patient to RocheCares team by providing the patient with Roche cares contact details.
-
How long will my patients benefit from Rochecares program?
Once patient’s eligibility is determined, they will benefit from the support throughout the treatment and enrollment period. Patients may withdraw the enrollment at any time.
Roche Lebanon S.A.R.L and/ or IQVIA may, without liability and at its sole discretion, decide to stop patient’s participation in the program or terminate the program at any time and you as well as your patients will be notified accordingly.
-
How my patient information is kept confidential?
Roche and IQVIA regard your privacy, as well as that of your patient, with the utmost respect and confidentiality. In order to ensure optimal support, documents, and information shall be collected by IQVIA. Data collected will be managed in accordance to applicable law under the laws of Lebanon and for the purposes specified in the signed Informed Consent Form.
-
Where is my data stored?
The Data will be stored on IQVIAs database hosted and processed by IQVIA.
-
Is NSSF pre-approval needed for patient program enrollment?
NSSF pre-approval is required for the enrollment of patients prescribed with in-hospital treatments.
Stay connected
In case of any adverse event occurring with any Roche Product, please report to Roche Local Safety Line +961 76 700 322 , or forward details to: beirut.safety_reporting.bs1@roche.com.
Date: November 2021. M-LB-00000476